A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer
The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) advanced breast cancer that have certain disease characteristics.
Metastatic Breast Cancer
DRUG: Abemaciclib|DRUG: Nonsteroidal Aromatase Inhibitor (NSAI)
Progression Free Survival (PFS), PFS, Baseline to Progressive Disease or Death from Any Cause (Estimated up to 26 Months)|Objective Response Rate (ORR): Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR), ORR, Baseline to Objective Disease Progression (Estimated up to 26 Months)
Duration of Response (DoR), DoR, Date of CR or PR to Date of Objective Disease Progression or Death from Any Cause (Estimated up to 26 Months)|Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response of CR, PR, or Stable Disease (SD), DCR, Baseline to Objective Disease Progression (Estimated up to 26 Months)|Clinical Benefit Rate (CBR): Proportion of Participants with Best Overall Response of CR, PR, or SD with Duration of SD for at Least 6 Months, CBR, Date of CR, PR or SD to 6 Months Post CR, PR or SD (Estimated up to 26 Months)|Time to Response (TTR), TTR, Baseline to Date of CR or PR (Estimated up to 26 Months)
The reason for this study is to see if the drug abemaciclib in combination with nonsteroidal aromatase inhibitors (anastrozole or letrozole) is effective in participants with Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) advanced breast cancer that have certain disease characteristics.